重症患者急诊插管前预防性使用血管升压药:两项多中心临床试验的二次分析
该研究为两项多中心随机临床试验的二次分析,纳入2019年2月1日至2021年5月24日美国7个急诊科和17个ICU中1798例接受急诊插管的重症患者,其中187例(10%)在插管前接受了预防性血管升压药。采用一对一倾向匹配队列比较,主要终点为诱导至气管插管后2分钟内收缩压低于90 mm Hg的围插管期低血压。匹配后,预防性血管升压药与围插管期低血压风险降低无关(41% vs 32%,p=0.08),与收缩压较基线变化也无关(-12 vs -11 mm Hg,p=0.66)。作者认为,为处理潜在残余混杂,应通过随机临床试验检验预防性血管升压药对围插管结局的影响。
要点
- 在倾向匹配队列中,预防性血管升压药与围插管期低血压风险降低无关(41% vs 32%,p=0.08)。
- 预防性血管升压药与收缩压较基线变化无关(-12 vs -11 mm Hg,p=0.66)。
- 接受预防性血管升压药者更年长、APACHE II评分更高、更多诊断为脓毒症、诱导前收缩压更低、更可能插管前持续泵入血管升压药。
- 1798例急诊插管重症患者中仅187例(10%)接受了预防性血管升压药。
- 作者认为,为处理潜在残余混杂,应通过随机临床试验检验预防性血管升压药对围插管结局的影响。
适用人群与场景
- 2019年2月1日至2021年5月24日在美国7个急诊科和17个ICU接受急诊插管的重症患者,共1798例。
诊断标准与关键阈值
- 围插管期低血压定义为诱导至气管插管后2分钟内收缩压低于90 mm Hg。
研究设计与关键结果
- 研究类型:两项多中心随机临床试验的二次分析,采用一对一倾向匹配队列。
- 共纳入1798例接受急诊插管的重症患者,其中187例(10%)在插管前接受了预防性血管升压药。
- 与未接受预防性血管升压药者相比,接受者更年长、急性生理与慢性健康评分II更高、更可能诊断为脓毒症、诱导前收缩压更低、更可能插管前持续泵入血管升压药。
- 倾向匹配队列中,预防性血管升压药与围插管期低血压风险降低无关(41% vs 32%,p=0.08)。
- 倾向匹配队列中,预防性血管升压药与收缩压较基线变化无关(-12 vs -11 mm Hg,p=0.66)。
证据类型、等级与局限
- 证据类型:两项多中心随机临床试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,为处理潜在残余混杂,应通过随机临床试验检验预防性血管升压药对围插管结局的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Hypotension affects approximately 40% of critically ill patients undergoing emergency intubation and is associated with an increased risk of death. The objective of this study was to examine the association between prophylactic vasopressor administration and the incidence of peri-intubation hypotension and other clinical outcomes.
DESIGN: A secondary analysis of two multicenter randomized clinical trials. The clinical effect of prophylactic vasopressor administration was estimated using a one-to-one propensity-matched cohort of patients with and without prophylactic vasopressors.
SETTING: Seven emergency departments and 17 ICUs across the United States.
PATIENTS: One thousand seven hundred ninety-eight critically ill patients who underwent emergency intubation at the study sites between February 1, 2019, and May 24, 2021.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was peri-intubation hypotension defined as a systolic blood pressure less than 90 mm Hg occurring between induction and 2 minutes after tracheal intubation. A total of 187 patients (10%) received prophylactic vasopressors prior to intubation. Compared with patients who did not receive prophylactic vasopressors, those who did were older, had higher Acute Physiology and Chronic Health Evaluation II scores, were more likely to have a diagnosis of sepsis, had lower pre-induction systolic blood pressures, and were more likely to be on continuous vasopressor infusions prior to intubation. In our propensity-matched cohort, prophylactic vasopressor administration was not associated with reduced risk of peri-intubation hypotension (41% vs 32%; p = 0.08) or change in systolic blood pressure from baseline (-12 vs -11 mm Hg; p = 0.66).
CONCLUSIONS: The administration of prophylactic vasopressors was not associated with a lower incidence of peri-intubation hypotension in our propensity-matched analysis. To address potential residual confounding, randomized clinical trials should examine the effect of prophylactic vasopressor administration on peri-intubation outcomes.
参考来源
- Fuchita M, Pattee J, Russell DW, et al. Prophylactic Administration of Vasopressors Prior to Emergency Intubation in Critically Ill Patients: A Secondary Analysis of Two Multicenter Clinical Trials. Crit Care Explor. 2023. PMID: 37457916. doi:10.1097/CCE.0000000000000946
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。